Eli Lilly signed a license and research agreement with ABL Bio to develop therapeutics using ABL’s Grabody‑B blood‑brain barrier (BBB)‑penetrating platform. The deal carries up to $2.6 billion in milestones plus royalties and included a $40 million up‑front payment, signaling Big Pharma’s renewed appetite for CNS delivery platforms. Grabody‑B is designed to ferry large biologics across the BBB; Lilly’s pact is one of several recent high‑value transactions aiming to overcome CNS delivery bottlenecks. ABL will receive funding and retain research collaboration responsibilities while Lilly secures broad development and commercialization rights. The agreement underscores the sector trend of platform licensing to de‑risk CNS pipelines and may accelerate multiple brain‑targeted programs. Investors will track milestone pacing, candidate selection, and early translational readouts for evidence the shuttle confers clinical utility.